These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 20665620)

  • 21. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells.
    Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA
    Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
    Alexander BM; Chen MH; Carroll P; D'Amico AV
    Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
    Moyad MA; Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Adamovich E
    Urology; 2005 Dec; 66(6):1150-4. PubMed ID: 16360430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy.
    Bañez LL; Klink JC; Jayachandran J; Lark AL; Gerber L; Hamilton RJ; Masko EM; Vollmer RT; Freedland SJ
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):722-8. PubMed ID: 20160265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
    Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
    Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human prostate cancer progression models and therapeutic intervention.
    Chung LW; Kao C; Sikes RA; Zhau HE
    Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
    Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
    J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statins and prostate cancer risk: a case-control study.
    Shannon J; Tewoderos S; Garzotto M; Beer TM; Derenick R; Palma A; Farris PE
    Am J Epidemiol; 2005 Aug; 162(4):318-25. PubMed ID: 16014776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific antigen in clinical practice.
    Loeb S; Catalona WJ
    Cancer Lett; 2007 Apr; 249(1):30-9. PubMed ID: 17258389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins in nephrotic syndrome: a new weapon against tissue injury.
    Buemi M; Nostro L; Crascì E; Barillà A; Cosentini V; Aloisi C; Sofi T; Campo S; Frisina N
    Med Res Rev; 2005 Nov; 25(6):587-609. PubMed ID: 16075407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer.
    Ornstein DK; Smith DS; Humphrey PA; Catalona WJ
    J Urol; 1998 Apr; 159(4):1234-7. PubMed ID: 9507843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.
    Marks LS; Andriole GL; Fitzpatrick JM; Schulman CC; Roehrborn CG
    J Urol; 2006 Sep; 176(3):868-74. PubMed ID: 16890642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statins: protectors or pretenders in prostate cancer?
    Moon H; Hill MM; Roberts MJ; Gardiner RA; Brown AJ
    Trends Endocrinol Metab; 2014 Apr; 25(4):188-96. PubMed ID: 24462080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
    Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E
    J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource.
    Datta MW; Dhir R; Dobbin K; Bosland MC; Melamed J; Becich MJ; Orenstein JM; Kajdacsy-Balla AA; Patel A; Macias V; Berman JJ
    J Urol; 2005 May; 173(5):1546-51. PubMed ID: 15821483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins and prostate cancer prevention: where we are now, and future directions.
    Murtola TJ; Visakorpi T; Lahtela J; Syvälä H; Tammela TLj
    Nat Clin Pract Urol; 2008 Jul; 5(7):376-87. PubMed ID: 18542103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
    Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
    Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.